Progressive recruitment of cortical and striatal regions by inducible postsynaptic density transcripts after increasing doses of antipsychotics with different receptor profiles: Insights for psychosis treatment

European Neuropsychopharmacology

Volumn 25, Issue 4, 2015, Pages 566-582

  de Bartolomeis, Andrea ^a   Iasevoli, Felice ^a   Marmo, Federica ^a   Buonaguro, Elisabetta F ^a   Eramo, Anna ^b   Rossi, Rodolfo ^a   Avvisati, Livia ^a   Latte, Gianmarco ^a   Tomasetti, Carmine ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b LUNDBECK RESEARCH USA   (United States)

Author keywords

Asenapine; Bipolar disorder; Haloperidol; Homer; Immediate early genes; Schizophrenia

Indexed keywords

ASENAPINE; HALOPERIDOL; IMMEDIATE EARLY PROTEIN; PROTEIN HOMER 1A; PROTEIN HOMER 1B; PROTEIN HOMER 1C; CARRIER PROTEIN; DLGH4 PROTEIN, RAT; EARLY GROWTH RESPONSE FACTOR 1; EGR1 PROTEIN, HUMAN; MEMBRANE PROTEIN; MESSENGER RNA; NEUROLEPTIC AGENT; PROTEIN BINDING; PROTEIN HOMER; PROTEIN V FOS; SIGNAL PEPTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; CONTROLLED STUDY; DRUG DOSE INCREASE; GENE EXPRESSION; IMMEDIATE EARLY GENE; LOCOMOTION; MALE; NERVE CELL PLASTICITY; NEUROMODULATION; NEUROPHYSIOLOGICAL RECRUITMENT; NONHUMAN; ONCOGENE C FOS; POSTSYNAPTIC DENSITY; PRIORITY JOURNAL; RANDOMIZATION; RAT; STRIATE CORTEX; AIDS RELATED COMPLEX; ANALYSIS OF VARIANCE; ANIMAL; CORPUS STRIATUM; DOSE RESPONSE; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MOTOR ACTIVITY; NONPARAMETRIC TEST; SPRAGUE DAWLEY RAT;

AIDS-RELATED COMPLEX; ANALYSIS OF VARIANCE; ANIMALS; ANTIPSYCHOTIC AGENTS; CARRIER PROTEINS; CEREBRAL CORTEX; CORPUS STRIATUM; DOSE-RESPONSE RELATIONSHIP, DRUG; EARLY GROWTH RESPONSE PROTEIN 1; GENE EXPRESSION REGULATION; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MEMBRANE PROTEINS; MOTOR ACTIVITY; ONCOGENE PROTEINS V-FOS; POST-SYNAPTIC DENSITY; PROTEIN BINDING; RATS; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER; STATISTICS, NONPARAMETRIC;

EID: 84928206840     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2015.01.003     Document Type: Article

References (49)

1. Ambesi-Impiombato A., D'Urso G., Muscettola G., de Bartolomeis A. Method for quantitative in situ hybridization histochemistry and image analysis applied for Homer1a gene expression in rat brain. Brain Res. Brain Res. Protoc. 2003, 11:189-196.
2. Ambesi-Impiombato A., Panariello F., Dell'aversano C., Tomasetti C., Muscettola G., de Bartolomeis A. Differential expression of Homer 1 gene by acute and chronic administration of antipsychotics and dopamine transporter inhibitors in the rat forebrain. Synapse 2007, 61:429-439.
3. Andersen M.P., Pouzet B. Effects of acute versus chronic treatment with typical or atypical antipsychotics on d-amphetamine-induced sensorimotor gating deficits in rats. Psychopharmacology (Berlin) 2001, 156:291-304.
4. Arnt J. Pharmacological differentiation of classical and novel antipsychotics. Int. Clin. Psychopharmacol. 1998, 13(Suppl. 3):S7-S14.
5. Beauvais G., Jayanthi S., McCoy M.T., Ladenheim B., Cadet J.L. Differential effects of methamphetamine and SCH23390 on the expression of members of IEG families of transcription factors in the rat striatum. Brain Res. 2010, 1318:1-10.
6. Bertran-Gonzalez J., Bosch C., Maroteaux M., Matamales M., Herve D., Valjent E., Girault J.A. Opposing patterns of signaling activation in dopamine D1 and D2 receptor-expressing striatal neurons in response to cocaine and haloperidol. J. Neurosci. 2008, 28:5671-5685.
7. de Bartolomeis, A., Buonaguro, E.F., Iasevoli, F., Tomasetti, C., 2014a. The emerging role of dopamine-glutamate interaction and of the postsynaptic density in bipolar disorder pathophysiology: implications for treatment. J. Psychopharmacol.
8. de Bartolomeis A., Latte G., Tomasetti C., Iasevoli F. Glutamatergic postsynaptic density protein dysfunctions in synaptic plasticity and dendritic spines morphology: relevance to schizophrenia and other behavioral disorders pathophysiology, and implications for novel therapeutic approaches. Mol. Neurobiol. 2014, 49:484-511.
9. de Bartolomeis A., Tomasetti C. Calcium-dependent networks in dopamine-glutamate interaction: the role of postsynaptic scaffolding proteins. Mol. Neurobiol. 2012, 46:275-296.
10. de Greef R., Maloney A., Olsson-Gisleskog P., Schoemaker J., Panagides J. Dopamine D2 occupancy as a biomarker for antipsychotics: quantifying the relationship with efficacy and extrapyramidal symptoms. Am. Assoc. Pharm. Sci. J. 2011, 13:121-130.
11. Franberg O., Marcus M.M., Ivanov V., Schilstrom B., Shahid M., Svensson T.H. Asenapine elevates cortical dopamine, noradrenaline and serotonin release. Evidence for activation of cortical and subcortical dopamine systems by different mechanisms. Psychopharmacology (Berlin) 2009, 204:251-264.
12. Franberg O., Marcus M.M., Svensson T.H. Involvement of 5-HT2A receptor and alpha2-adrenoceptor blockade in the asenapine-induced elevation of prefrontal cortical monoamine outflow. Synapse 2012, 66:650-660.
13. Franberg O., Wiker C., Marcus M.M., Konradsson A., Jardemark K., Schilstrom B., Shahid M., Wong E.H., Svensson T.H. Asenapine, a novel psychopharmacologic agent: preclinical evidence for clinical effects in schizophrenia. Psychopharmacology (Berlin) 2008, 196:417-429.
14. Fumagalli F., Frasca A., Racagni G., Riva M.A. Antipsychotic drugs modulate Arc expression in the rat brain. Eur. Neuropsychopharmacol. 2009, 19:109-115.
15. Hasan A., Falkai P., Wobrock T., Lieberman J., Glenthoj B., Gattaz W.F., Thibaut F., Moller H.J., WFSBP Task force on Treatment Guidelines for Schizophrenia World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, Part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects. World J. Biol. Psychiatry 2013, 14:2-44.
16. Hasan A., Falkai P., Wobrock T., Lieberman J., Glenthoj B., Gattaz W.F., Thibaut F., Moller H.J., World Federation of Societies of Biological Psychiatry Task Force on Treatment Guidelines for Schizophrenia World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. World J. Biol. Psychiatry 2012, 13:318-378.
17. Iasevoli F., Ambesi-Impiombato A., Fiore G., Panariello F., Muscettola G., de Bartolomeis A. Pattern of acute induction of Homer1a gene is preserved after chronic treatment with first- and second-generation antipsychotics: effect of short-term drug discontinuation and comparison with Homer1a-interacting genes. J. Psychopharmacol. 2011, 25:875-887.
18. Iasevoli F., Fiore G., Cicale M., Muscettola G., de Bartolomeis A. Haloperidol induces higher Homer1a expression than risperidone, olanzapine and sulpiride in striatal sub-regions. Psychiatry Res. 2010, 177:255-260.
19. Iasevoli F., Tomasetti C., Ambesi-Impiombato A., Muscettola G., de Bartolomeis A. Dopamine receptor subtypes contribution to Homer1a induction: insights into antipsychotic molecular action. Prog. Neuropsychopharmacol. Biol. Psychiatry 2009, 33:813-821.
20. Iasevoli F., Tomasetti C., Buonaguro EF., de Bartolomeis A. The glutamatergic aspects of schizophrenia molecular pathophysiology: role of the postsynaptic density, and implications for treatment. Curr Neuropharmacol. 2014, 12(3):219-238.
21. Iasevoli F., Buonaguro EF., Sarappa C., Marmo F., Latte G., Rossi R., Eramo A., Tomasetti C., de Bartolomeis A. Regulation of postsynaptic plasticity genes' expression and topography by sustained dopamine perturbation and modulation by acute memantine: relevance to schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2014, 3(54):299-314.
22. Jardemark K., Marcus M.M., Shahid M., Svensson T.H. Effects of asenapine on prefrontal N-methyl-D-aspartate receptor-mediated transmission: involvement of dopamine D1 receptors. Synapse 2010, 64:870-874.
23. Kumar V., Fahey P.G., Jong Y.J., Ramanan N., O'Malley K.L. Activation of intracellular metabotropic glutamate receptor 5 in striatal neurons leads to up-regulation of genes associated with sustained synaptic transmission including Arc/Arg3.1 protein. J. Biol. Chem. 2012, 287:5412-5425.
24. Lahti A.C., Weiler M.A., Medoff D.R., Tamminga C.A., Holcomb H.H. Functional effects of single dose first- and second-generation antipsychotic administration in subjects with schizophrenia. Psychiatry Res. 2005, 139:19-30.
25. Moy S.S., Fernandes A., Qian Y., Rotella D.J., Kostrewa R.M., Breese G.R. Effect of acute and chronic olanzapine treatment on phencyclidine-induced behavioral sensitization in rats with neonatal dopamine loss. Pharmacol. Biochem. Behav. 2004, 78:47-56.
26. Natesan S., Reckless G.E., Nobrega J.N., Fletcher P.J., Kapur S. Dissociation between in vivo occupancy and functional antagonism of dopamine D2 receptors: comparing aripiprazole to other antipsychotics in animal models. Neuropsychopharmacology 2006, 31:1854-1863.
27. Obara I., Goulding S.P., Gould A.T., Lominac K.D., Hu J.H., Zhang P.W., von Jonquieres G., Dehoff M., Xiao B., Seeburg P.H., Worley P.F., Klugmann M., Szumlinski K.K. Homers at the interface between reward and pain. Front Psychiatry 2013, 4:39.
28. Paxinos G., Watson C. The Rat Brain in Stereotaxic Coordinates 1997, Academic Press Inc., Sidney, Australia.
29. Polese D., de Serpis A.A., Ambesi-Impiombato A., Muscettola G., de Bartolomeis A. Homer 1a gene expression modulation by antipsychotic drugs: involvement of the glutamate metabotropic system and effects of D-cycloserine. Neuropsychopharmacology 2002, 27:906-913.
30. Potkin S.G. Asenapine: a clinical overview. J. Clin, Psychiatry 2011, 72(Suppl. 1):S14-S18.
31. Potkin S.G., Phiri P., Szegedi A., Zhao J., Alphs L., Cazorla P. Long-term effects of asenapine or olanzapine in patients with persistent negative symptoms of schizophrenia: a pooled analysis. Schizophr. Res. 2013, 150:442-449.
32. Robbins M.J., Critchlow H.M., Lloyd A., Cilia J., Clarke J.D., Bond B., Jones D.N., Maycox P.R. Differential expression of IEG mRNA in rat brain following acute treatment with clozapine or haloperidol: a semi-quantitative RT-PCR study. J. Psychopharmacol. 2008, 22:536-542.
33. Robertson G.S., Fibiger H.C. Neuroleptics increase c-fos expression in the forebrain: contrasting effects of haloperidol and clozapine. Neuroscience 1992, 46:315-328.
34. Robertson G.S., Matsumura H., Fibiger H.C. Induction patterns of Fos-like immunoreactivity in the forebrain as predictors of atypical antipsychotic activity. J. Pharmacol. Exp. Ther. 1994, 271:1058-1066.
35. Sedvall G.C. Neurobiological correlates of acute neuroleptic treatment. Int. Clin. Psychopharmacol. 1996, 11(Suppl. 2):S41-S46.
36. Shahid M., Walker G.B., Zorn S.H., Wong E.H. Asenapine: a novel psychopharmacologic agent with a unique human receptor signature. J. Psychopharmacol. 2009, 23:65-73.
37. Snigdha S., Idris N., Grayson B., Shahid M., Neill J.C. Asenapine improves phencyclidine-induced object recognition deficits in the rat: evidence for engagement of a dopamine D1 receptor mechanism. Psychopharmacology (Berlin) 2011, 214:843-853.
38. Szumlinski K.K., Lominac K.D., Kleschen M.J., Oleson E.B., Dehoff M.H., Schwarz M.K., Seeburg P.H., Worley P.F., Kalivas P.W. Behavioral and neurochemical phenotyping of Homer1 mutant mice: possible relevance to schizophrenia. Genes Brain Behav. 2005, 4:273-288.
39. Tait D.S., Marston H.M., Shahid M., Brown V.J. Asenapine restores cognitive flexibility in rats with medial prefrontal cortex lesions. Psychopharmacology (Berlin) 2009, 202:295-306.
40. Tarazi F.I., Choi Y.K., Gardner M., Wong E.H., Henry B., Shahid M. Asenapine exerts distinctive regional effects on ionotropic glutamate receptor subtypes in rat brain. Synapse 2009, 63:413-420.
41. Tarazi F.I., Moran-Gates T., Wong E.H., Henry B., Shahid M. Differential regional and dose-related effects of asenapine on dopamine receptor subtypes. Psychopharmacology (Berlin) 2008, 198:103-111.
42. Tarazi F.I., Moran-Gates T., Wong E.H., Henry B., Shahid M. Asenapine induces differential regional effects on serotonin receptor subtypes. J. Psychopharmacol. 2010, 24:341-348.
43. Tarazi F.I., Shahid M. Asenapine maleate: a new drug for the treatment of schizophrenia and bipolar mania. Drugs Today (Barc.) 2009, 45:865-876.
44. Tomasetti C., Dell'Aversano C., Iasevoli F., de Bartolomeis A. Homer splice variants modulation within cortico-subcortical regions by dopamine D2 antagonists, a partial agonist, and an indirect agonist: implication for glutamatergic postsynaptic density in antipsychotics action. Neuroscience 2007, 150:144-158.
45. Tomasetti C., Dell'Aversano C., Iasevoli F., Marmo F., de Bartolomeis A. The acute and chronic effects of combined antipsychotic-mood stabilizing treatment on the expression of cortical and striatal postsynaptic density genes. Prog. Neuropsychopharmacol. Biol. Psychiatry 2011, 35:184-197.
46. Tost H., Braus D.F., Hakimi S., Ruf M., Vollmert C., Hohn F., Meyer-Lindenberg A. Acute D2 receptor blockade induces rapid, reversible remodeling in human cortical-striatal circuits. Nat. Neurosci. 2010, 13:920-922.
47. Unal C.T., Beverley J.A., Willuhn I., Steiner H. Long-lasting dysregulation of gene expression in corticostriatal circuits after repeated cocaine treatment in adult rats: effects on zif 268 and homer 1a. Eur. J. Neurosci. 2009, 29:1615-1626.
48. Willuhn I., Sun W., Steiner H. Topography of cocaine-induced gene regulation in the rat striatum: relationship to cortical inputs and role of behavioural context. Eur J Neurosci. 2003, 17(5):1053-1066.
49. Wood M.D., Scott C., Clarke K., Cato K.J., Patel N., Heath J., Worby A., Gordon L., Campbell L., Riley G., Davies C.H., Gribble A., Jones D.N. Pharmacological profile of antipsychotics at monoamine receptors: atypicality beyond 5-HT2A receptor blockade. CNS Neurol. Disord. Drug Targets 2006, 5:445-452.